Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder
Mikhail Sergeevich Zastrozhin,1,2 Vadim Markovich Brodyansky,3 Valentin Yurievich Skryabin,4 Elena Anatolievna Grishina,5 Dmitry Vladimirovich Ivashchenko,5 Kristina Anatolievna Ryzhikova,5 Ludmila Mikhaylovna Savchenko,1 Alexander Olegovich Kibitov,3 Evgeny Alekseevich Bryun,1,4 Dmitry Alekseevich...
Main Authors: | Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-07-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacodynamic-genetic-polymorphisms-affect-adverse-drug-reactions-of-peer-reviewed-article-PGPM |
Similar Items
-
The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction
by: Zastrozhin MS, et al.
Published: (2017-12-01) -
The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
by: Sychev DA, et al.
Published: (2016-09-01) -
Pharmacogenetics of alcohol addiction: current perspectives
by: Zastrozhin MS, et al.
Published: (2019-07-01) -
Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
by: Zastrozhin MS, et al.
Published: (2018-06-01) -
The DRD2/ANKK1 Taq1A polymorphism in CYP2D6 extensive metabolizers is associated with the severity of extrapyramidal side effects of haloperidol treatment in schizophrenia spectrum disorders patients
by: A. Kibitov, et al.
Published: (2021-04-01)